Results 181 to 190 of about 50,045 (313)

Safety and effectiveness of albutrepenonacog alfa in Japanese patients with hemophilia B: Interim report of a post-marketing surveillance study

, 2022
Teruhisa Fujii, Keiji Nogami, Midori Shima, Hiromi TERAYAMA, Fumihiko SHIMIZU, Masashi Taki   +5 more
openalex   +2 more sources

Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom

European Journal of Haematology, Volume 116, Issue 1, Page 66-74, January 2026.
ABSTRACT Objectives We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom. Methods Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the on‐demand ...
Mike Laffan, Heena Howitt, Cheryl Jones, Sarah Brighton, Rosa Willock, Anna Sanigorska, Oliver Heard   +6 more
wiley   +1 more source

Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen. [PDF]

Front Pediatr
Terasaka N, Mckeand W.
europepmc   +1 more source

The human genes for hemophilia A and hemophilia B flank the X chromosome fragile site at Xq27.3. [PDF]

, 1985
Michele Purrello, Becky Alhadeff, Diane Esposito, Piroska E. Szabó, Mariano Rocchi, Martha Truett, Frank R. Masiarz, M. Siniscalco   +7 more
openalex   +1 more source

Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom

European Journal of Haematology, Volume 116, Issue 1, Page 75-84, January 2026.
ABSTRACT Objectives We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom. Methods Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the ...
Mike Laffan, Heena Howitt, Cheryl Jones, Sarah Brighton, Rosa Willock, Anna Sanigorska, Oliver Heard   +6 more
wiley   +1 more source

Gene therapy as an innovative approach to the treatment of hemophilia B-a review. [PDF]

J Appl Genet
Wróblewska K, Bieszczad D, Popławska M, Ziętara KJ, Zajączkowska M, Filip A.   +5 more
europepmc   +1 more source

Retroperitoneal hematoma complicated with colocutaneous fistula in a case of severe hemophilia B

Haydar Zengin, Melda Cömert, Tuba Bulduk, Rahman Şenocak   +3 more
openalex   +1 more source

PND33 UTILIZING A PAPER STANDARD GAMBLE INSTRUMENT TO ASSESS HEALTH UTILITY IN PATIENTS WITH HEMOPHILIA B [PDF]

, 2011
Mary Lou, Z.Y. Zhou, Femida Gwadry‐Sridhar, Jiat Ling Poon, Jason N. Doctor, Marion A. Koerper, Megan M. Ullman, K. M. JOHNSON   +7 more
openalex   +1 more source

Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug

HLA, Volume 107, Issue 1, January 2026.
ABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Hannah C. M. Schenk, Ilse Gille, Carolt Arana, Jordi Rovira, Eduard Palou, Fritz Diekmann, Dave L. Roelen, Mirjam H. M. Heemskerk, Sebastiaan Heidt   +8 more
wiley   +1 more source

Chinese guidance for the clinical application of adeno-associated virus vector-based gene therapy for hemophilia B (2025). [PDF]

Blood Sci
Xue F, Hu Y, Yang R, Sun J, Yang L, Wang X, Yu Z, Zhu T, Zhou H, Zhou Z, Yan Z, Du X, Zheng C, Liu W, Zhou R, Dai J, Yin J, Wang H, Tang LV, Chen S, Cheng H, Zhu M, Wang S, Song Y, Zhang P, Zhang L.   +25 more
europepmc   +1 more source